Pediatric Neuroblastoma Treatment Market
Pediatric Neuroblastoma Treatment Market Study by Immunotherapy, Chemotherapy, and Others from 2023 to 2033
Analysis of Pediatric Neuroblastoma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
- FACT4694MR
- 21 Mar 2023
- Healthcare
- 170 Pages
- 25 Tables
- 76 Figures
- Base Value(2023): 2.1 Bn
- Forecast Value (2033): 5.3 Bn
- CAGR (2033): 9.7%
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecast, by Therapy Type
- 6.1. Immunotherapy
- 6.2. Chemotherapy
- 6.3. Others
- 7. Global Market Analysis and Forecast, by End-user
- 7.1. Hospital Pharmacies
- 7.2. Retail Pharmacies & Drug Stores
- 8. Global Market Analysis and Forecast, by Region
- 8.1. North America
- 8.2. Europe
- 8.3. Rest of the World
- 9. North America Market Analysis and Forecast
- 10. Europe Market Analysis and Forecast
- 11. Rest of the World Market Analysis and Forecast
- 12. Company Profiles
- 12.1. United Therapeutics Corporation
- 12.2. APEIRON Biologics AG
- 12.3. Baxter
- 12.4. Cellectar Biosciences, Inc.
- 12.5. Pfizer, Inc.
- 12.6. MacroGenics, Inc.
- 12.7. Bayer AG
List Of Table
Table 01: List of acronyms used in the report
Table 02: Global Market: Pipeline Analysis
Table 03: Global Market: Pipeline Analysis
Table 04: Global Market: Pipeline Analysis
Table 05: Global Market: Pipeline Analysis
Table 06: Global Market: Pipeline Analysis
Table 07: Global Market: Pipeline Analysis
Table 08: Global Market: Pipeline Analysis
Table 09: Global Market: Pipeline Analysis
Table 10: Global Market: Pipeline Analysis
Table 11: Global Market: Pipeline Analysis
Table 12: Global Market: Pipeline Analysis
Table 13: Global Market: Pipeline Analysis
Table 14: Global Market: Pipeline Analysis
Table 15: Global Market Value (US$ Mn) Forecast, by Therapy Type, 2023 to 2033
Table 16: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 17: Global Market Value (US$ Mn) Forecast, by Region, 2023 to 2033
Table 18: North America Market Value (US$ Mn) Forecast, by Country, 2023 to 2033
Table 19: North America Market Value (US$ Mn) Forecast, by Therapy Type, 2023 to 2033
Table 20: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 22: Europe Market Value (US$ Mn) Forecast, by Therapy Type, 2023 to 2033
Table 23: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 24: Rest of the World Market Value (US$ Mn) Forecast, by Therapy Type, 2023 to 2033
Table 25: Rest of the World Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
List Of Figures
Figure 01: Global Market
Figure 02: Global Market Size (US$ Mn), by Therapy Type, 2022
Figure 03: Global Market Segments with Leading Market Share (%), 2022
Figure 04: Global Market Value (US$ Mn) Forecast, 2023 to 2033
Figure 05: Global Market Value Share (%), by Therapy Type, 2022
Figure 06: Global Market Value Share (%), by Distribution Channel, 2022
Figure 07: Global Market Value Share (%), by Region, 2022
Figure 08: Key Industry Events
Figure 09: Porter’s Five Forces Analysis
Figure 10: Epidemiology of Neuroblastoma
Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets
Figure 12: Epidemiology of Neuroblastoma Key Research Findings
Figure 13: Epidemiology of Neuroblastoma, by Country
Figure 14: Epidemiology of Neuroblastoma, by Country
Figure 15: Epidemiology of Neuroblastoma, by Country
Figure 16: Key Unmet Needs in the Market
Figure 17: Global Market: Rate of Metastasis to the Brain
Figure 18: Global Market: Rate of Metastasis to the Brain
Figure 19: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 20: Global Market: Neuroblastoma Relapse/Refractory cases
Figure 21: Global Market: Utilization of MIBG-131
Figure 22: Global Market: Utilization of MIBG-131
Figure 23: Global Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 24: Global Market Attractiveness, by Therapy Type, 2023 to 2033
Figure 25: Global Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2023 to 2033
Figure 26: Global Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2023 to 2033
Figure 27: Global Market Revenue (US$ Mn) Forecast, by Others, 2023 to 2033
Figure 28: Global Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 29: Global Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 30: Global Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2023 to 2033
Figure 31: Global Market Revenue (US$ Mn) Forecast, by Retail Pharmacies &Drug Stores, 2023 to 2033
Figure 32: Global Market Value Share (%), by Region, 2023 and 2033
Figure 33: Global Market Attractiveness, by Region, 2023 to 2033
Figure 34: North America Market Revenue (US$ Mn) forecast, 2023 to 2033
Figure 35: North America Market Value Share (%), by Country, 2023 and 2033
Figure 36: North America Market Attractiveness, by Country, 2023 to 2033
Figure 37: North America Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 38: North America Market Attractiveness, by Therapy Type, 2023 to 2033
Figure 39: North America Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 40: North America Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 41: Europe Market Revenue (US$ Mn) Forecast, 2023 to 2033
Figure 42: Europe Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 43: Europe Market Attractiveness, by Country/Sub-region, 2023 to 2033
Figure 44: Europe Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 45: Europe Market Attractiveness, by Therapy Type, 2023 to 2033
Figure 46: Europe Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 47: Europe Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 48: Rest of the World Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023 to 2033
Figure 49: Rest of the World Market Value Share (%), by Therapy Type, 2023 and 2033
Figure 50: Rest of the World Market Attractiveness, by Therapy Type, 2023 to 2033
Figure 51: Rest of the World Market Value Share (%), by Distribution Channel, 2023 and 2033
Figure 52: Rest of the World Market Attractiveness, by Distribution Channel, 2023 to 2033
Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2022
Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2018 to 2022
Figure 57: United Therapeutics Corporation: SWOT Analysis
Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands
Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2018 to 2022
Figure 62: MacroGenics, Inc.: SWOT Analysis
Figure 63: APEIRON Biologics AG: SWOT Analysis
Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013 to 2022
Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2022
Figure 66: Baxter pipeline of generic products, 2018 to 2023
Figure 67: Baxter: SWOT Analysis
Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2018 to 2022
Figure 70: Pfizer Inc.: SWOT Analysis
Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis
Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2022
Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2022
Figure 76: Bayer Group: SWOT Analysis
Pediatric Neuroblastoma Treatment Market